



03 CO #3

PTO/SB/21 (08-00)

Approved for use through 10/31/02. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)


Total Number Of Pages In This Submission	8	Attorney Docket No.	252312006103
--	---	---------------------	--------------

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO-1449 (4 Pages) Return Receipt Postcard
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement (3 Pages)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT


Firm or Individual Name	Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 Madeline I. Johnston (Registration No. 36,174)
Signature	
Date	March 25, 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on March 25, 2002.


Michael Boyd


Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



PATENT
Docket No. 252312006103

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on March 25, 2002.


Michael Boyd

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Edward J. VICTORIA et al.

Serial No.: 10/044,844

Filing Date: January 10, 2002

For: APL IMMUNOREACTIVE PEPTIDES,
CONJUGATES THEREOF AND
METHODS OF TREATMENT FOR APL
ANTIBODY-MEDIATED
PATHOLOGIES

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 AND § 1.98**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in Information Disclosure Statements and Office Actions, directed to the related applications: Serial Number 08/760,508, filed December 5, 1996, and Serial Number 09/160,513, filed September 24, 1998, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of * is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.


Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **252312006103**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 25, 2002

Respectfully submitted,

By: 

Madeline I. Johnston
Registration No. 36,174

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5840
Facsimile: (650) 494-0792



Form PTO-1449		Doc. No. 252312006103	Application Number 10/044,844
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Edward J. VICTORIA et al.	
		Filing Date January 10, 2002	Group Art Unit To Be Assigned
		Mailing Date March 25, 2002	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	8/1967	3,335,165	Johnson et al.			
	2.	11/1986	4,625,057	Springmann et al.			
	3.	1/1992	5,082,967	Heuckeroth et al.			
	4.	6/1992	5,120,748	Caprathe et al.			
	5.	11/10/92	5,162,515	Conrad et al.			
	6.	12/07/93	5,268,454	Barstad et al.			
	7.	01/04/94	5,276,013	Conrad et al.			
	8.	09/06/94	5,344,758	Krilis et al.			
	9.	2/1995	5,393,751	Sendai et al.			
	10.	12/05/95	5,472,883	Matsuura et al.			
	11.	03/12/96	5,498,538	Kay et al.			
	12.	04/09/96	5,506,110	Matsuura et al.			
	13.	09/03/96	5,552,391	Coutts et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	14.	11/1968	1,134,314	Great Britain			
	15.	11/1968	411,409	Europe			
	16.	10/17/91	WO 91 15722 A	PCT			Abstract Only
	17.	08/12/92	EP 0 498 658 A2	Europe			
	18.	03/15/95	EP 0 642 798 A	Europe			
	19.	12/19/96	WO 96 40197 A	PCT			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner	Ref.	Title
EXAMINER:		DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.		




Form PTO-1449		Document Number 252312006103	Application Number 10/044,844
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant	Edward J. VICTORIA et al.
		Filing Date January 10, 2002	Group Art Unit To Be Assigned
		Mailing Date March 25, 2002	

Initials	No.	
	20.	Aichele et al., "Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model," <i>Proc. Natl. Acad. Sci. USA</i> 91:444-448 (1994)
	21.	Arvieux et al., "Platelet activating properties of murine monoclonal antibodies to β_2 -glycoprotein 1," <i>Thromb. Haemostas.</i> 70:336-341 (1993)
	22.	Bakimer et al., "Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3)," <i>J. Clin. Invest.</i> 89:1558-1563 (1992)
	23.	Balass et al., "Identification of a hexapeptide that mimics a conformation-dependent binding site of acetylcholine receptor by use of a phage-epitope library," <i>Proc. Natl. Acad. Sci. USA</i> 90:10638-10642 (1993)
	24.	Barbas III et al., "Assembly of combinatorial antibody libraries on phage surfaces: The gene III site," <i>Proc. Natl. Acad. Sci. USA</i> 88:7978-7982 (1991)
	25.	Blank et al., "Induction of anti-phospholipid syndrome in naïve mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 88:3069-3073 (1991)
	26.	Bliznyuk et al. <i>Chem Abst.</i> : 138768 (1984)
	27.	Brighton et al., "Antiphospholipid antibodies and thrombosis" <i>Balliere's Clin. Haematol.</i> 7(3):541-557. (1994)
	28.	Cesareni, "Peptide display on filamentous phage capsids," <i>FEBS Lett.</i> 307:66-70 (1992)
	29.	Cwirla et al., "Peptides on phage: A vast library of peptides for identifying ligands," <i>Proc. Natl. Acad. Sci. USA</i> 87:6378-6382 (1990)
	30.	Dower et al., "High efficiency transformation of <i>E. coli</i> by high voltage electroporation," <i>Nucleic Acid Res.</i> 16:6127-6145 (1988)
	31.	Elliott, "Anergy and suppression in B-cell responses," <i>Scand. J. Immunol.</i> 36:761-767 (1992)
	32.	Friesen et al. <i>Chem. Abst.</i> : 84487 (1981)
	33.	Galli et al., "Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor," <i>Lancet</i> 1544-1547 (1990)
	34.	Gharavi et al., "Induction of antiphospholipid antibodies by immunization with a 15-amino acid peptide spanning the phospholipid binding site of β_2 glycoprotein I" <i>J. Invest. Med.</i> 44:69A. (1996)
	35.	Haas et al., "Rapid sequencing of viral DNA from filamentous bacteriophage," <i>BioTechniques</i> 15:422-423, 426, 428-429 (1993)
	36.	Harris et al. (eds.) <i>Phospholipid-Binding Antibodies</i> , CRC Press, Boca Raton, FL (1991)
	37.	Harris, "Antiphospholipid antibodies," <i>Brit. J. Haemotol.</i> 74:1-9 (1990)
	38.	Hasselaar et al., "Crossreactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets," <i>Thromb. Haemostas.</i> 63:169-173 (1990)
	39.	Holmes et al., "A rapid boiling method for the preparation of bacterial plasmids," <i>Anal. Biochem.</i>

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.




Form PTO-1449		Docket Number 252312006103	Application Number 10/044,844
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Edward J. VICTORIA et al.	
		Filing Date January 10, 2002	Group Art Unit To Be Assigned
		Mailing Date March 25, 2002	

	144:193-197 (1981)
40.	Hunt et al., "The fifth domain of β_2 -glycoprotein 1 contains a phospholipid binding site (cys281-cys288) and a region recognized by anticardiolipin antibodies," <i>J. Immunol.</i> 152:653-659 (1994)
41.	Jones et al., "Antigenic specificity of anticardiolipin antibodies appears to depend on conformation of β_2 -glycoprotein 1," <i>Proc. 5th Intl. Symp. Antiphospholipid Antibodies</i> (September 9-12, 1992) Hyatt Regency San Antonio, Texas (Abstract S5) (4 pages total)
42.	Kandiah et al., "Epitope mapping studies of antiphospholipid antibodies and β_2 -GPI using synthetic peptides" <i>Lupus</i> 4(Suppl 1):S7-S11. (1995)
43.	Kato et al., "Amino acid sequence and location of the disulfide bonds in bovine β_2 -glycoprotein 1: The presence of five sushi domains," <i>Biochem.</i> 30:11687-11694 (1991)
44.	Kitano et al. <i>Chem Abst.</i> : 716757 (1977)
45.	Kunz. <i>Chem. Abst.</i> : 536379 (1977)
46.	Laduranty et al. <i>Chem Abst.</i> : 5540 (1988)
47.	Lauer et al., "Amino acid sequence of the region of β_2 -glycoprotein 1 (gp1) which mediates binding of autoantibodies to the cardiolipin-gp1 complex in humans," <i>Immunol.</i> 80:22-28 (1993)
48.	Lenstra et al. "Isolation of Sequences From a Random-Sequence Expression Library that Mimics Viral Epitopes," <i>J. Immunol. Methods</i> 152: 149-157 (1992)
49.	Luzzago et al., "Mimicking of discontinuous epitopes by phage-displayed peptides, I. Epitope mapping of human H ferritin using a phage library of constrained peptides," <i>Gene</i> 128:51-57 (1993)
50.	McCarty-Farid "Antiphospholipid antibodies in systemic lupus erythematosus and Sjorgen's syndrome" <i>Current Opinion in Rheumatology</i> 5:596-603. (1993)
51.	McConathy et al., "Isolation and characterization of other apolipoproteins," <i>Meth. Enzymol.</i> 128:296-310 (1986)
52.	McNeil et al., "Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β_2 -glycoprotein 1 (apolipoprotein H) <i>Proc. Natl. Acad. Sci.</i> 87:4120-4124 (1990)
53.	McNeil et al., "Immunology and clinical importance of antiphospholipid antibodies," <i>Adv. Immunol.</i> 49:193-280 (1991)
54.	Moos et al., "Recent advances in the generation of molecular diversity," <i>Ann. Reports Med. Chem.</i> 28:315-324 (1993)
55.	Nonaka et al., "Molecular cloning of mouse β_2 -glycoprotein 1 and mapping of the gene to chromosome 11," <i>Genomics</i> 13:1082-1087 (1992)
56.	Petri et al., "Diagnosis of antiphospholipid antibodies" <i>Rheumatic Disease Clinics of North America</i> , 20(2):443-469 (1994)
57.	Posnett et al., "A novel method for producing anti-peptide antibodies," <i>J. Biol. Chem.</i> 263:1719-1725 (1988)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449		Document Number 252312006103	Application Number 10/044,844
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Edward J. VICTORIA et al.	
		Filing Date January 10, 2002	Group Art Unit To Be Assigned
		Mailing Date March 25, 2002	

58.	Powell, "Peptide stability in drug development: In vitro peptide degradation in plasma and serum," <i>Ann. Reports Med. Chem.</i> 28:285-294 (1993)
59.	Reber et al., "Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies," <i>Thrombosis and Haemostat.</i> 73:444-452 (1995)
60.	Roubey et al., "Comparison of an enzyme-linked immunosorbent assay for antibodies to β_2 -glycoprotein I and a conventional anticardiolipin immunoassay" <i>Arthritis & Rheumatism</i> 39(9):1606-1607 (1996)
61.	Sambrook et al., <i>Molecular Cloning: A Laboratory Manual</i> 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). The title page and table of contents were included therewith.
62.	Sanger et al., "DNA sequencing with chain-terminating inhibitors," <i>Proc. Natl. Acad. Sci. USA</i> 74:5463-5467 (1977)
63.	Scott et al., "Searching for peptide ligands with an epitope library," <i>Science</i> 249:386-390 (1990)
64.	Scott, J.K., "Identifying lead peptides from epitope libraries," <i>Biological Approaches to Rational Drug Design</i> GN (CRC Press, Weiner, D.B. and Williams, W.V., eds., Boca Raton, FL, 1994), Chapter 1, pp. 1-28. The title page and table of contents were enclosed therewith.
65.	Smith et al., "Libraries of peptides and proteins displayed on filamentous phage," <i>Meth. Enzymol.</i> 217:228-257 (1993)
66.	Steinkasserer et al., "Activity, disulphide mapping and structural modelling of the fifth domain of human β_2 -glycoprotein 1," <i>FEBS Lett.</i> 313:193-197 (1992)
67.	Steinkasserer et al., "Complete nucleotide and deduced amino acid sequence of human β_2 -glycoprotein 1," <i>Biochem. J.</i> 277:387-391 (1991)
68.	Valesini et al., "A new player in the antiphospholipid syndrome: the β_2 glycoprotein I cofactor" <i>Autoimmunity</i> 14:105-110 (1992)
69.	Vermylen et al., "Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes?" <i>J. Clin. Lab. Med.</i> 120:10-12 (1992)
70.	Wagenknecht et al., "Changes in β_2 -glycoprotein 1 antigenicity induced by phospholipid binding," <i>Thromb. Haemostas.</i> 69:361-365 (1993)
71.	Wang et al., "Epitope specificity of monoclonal anti- β_2 -glycoprotein I antibodies derived from patients with the antiphospholipid syndrome" <i>J. Immunol.</i> 155:1629-1636 (1995)

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	